Poolbeg Pharma has reported encouraging pre-clinical results for POLB 001, a new treatment designed to reduce cytokine release syndrome (CRS), a serious side effect of cancer immunotherapies. The study, presented at the 66th American Society of Hematology Annual Meeting, showed that POLB 001 significantly alleviates CRS symptoms. Mark Sumeray, the company’s consultant Clinical Advisor, highlighted the statistical significance of the data, showing a dose-dependent reduction in clinical CRS and cytokine inhibition.
POLB 001 demonstrated its effectiveness in humanized mouse models bearing tumours, outperforming the current gold standard anti-TNF antibody, Adalimumab. When administered twice daily over five days, POLB 001 not only reduced CRS symptoms but also lowered peak levels of inflammatory cytokines, including TNF, IL-4, IL-6, IL-8, and MIP-1α. This positions POLB 001 as a promising prophylactic treatment, addressing a major unmet need in cancer immunotherapy.
With the encouraging results of these pre-clinical studies, POLB 001 is set to improve the safety and efficacy of cancer immunotherapies, potentially expanding their use to more patients. Poolbeg Pharma is now preparing for Phase 2 clinical trials, furthering their commitment to innovative treatments in critical areas of healthcare.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
